Ezequiel J. Molina
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ezequiel J. Molina has a total of 185 co-authors. Here are the top co-authors by number of shared publications:
- Farooq H. Sheikh
MedStar Heart and Vascular Institute, Georgetown University School of Medicine, Washington, DC, USA
8 shared publications - Mandeep R. Mehra
Mass General Brigham Heart and Vascular Institute and Harvard Medical School , Boston, MA
5 shared publications - Manreet Kaur Kanwar
Division of Cardiology, Department of Medicine, University of Chicago, Chicago, Illinois
5 shared publications Ajay Kadakkal
MedStar Heart and Vascular Institute Washington DC USA
4 shared publicationsMichael Hockstein
MedStar Heart and Vascular Institute Washington DC USA
4 shared publicationsNir Uriel
Division of Cardiology, Columbia University Irving Medical Center, New York-Presbyterian Hospital, New York, New York, USA
4 shared publications
Latest Publications
- Open Access
- 12 October 2026
- Published by Elsevier in Journal of Cardiac Failure
Real-World Adoption and Associated Outcomes of Aspirin Avoidance After HeartMate 3 Implantation: The PRAISE HM3 Study
- 12 October 2026
- Published by Elsevier in Journal of Cardiac Failure
Open AccessReal-World Adoption and Associated Outcomes of Aspirin Avoidance After HeartMate 3 Implantation: The PRAISE HM3 Study
- 27 August 2026
- Published by Elsevier in Journal of Cardiac Failure
- Vol. 32 (10) , 1781-1794
From Rescue to Interception: The PREVENT 2-LATE (PReserve Eligibility Via Early, Necessary Transfer) Framework for Advanced Heart Failure
- 27 August 2026
- Published by Elsevier in Journal of Cardiac Failure
- Vol. 32 (10) , 1781-1794
From Rescue to Interception: The PREVENT 2-LATE (PReserve Eligibility Via Early, Necessary Transfer) Framework for Advanced Heart Failure
- 26 April 2026
- Published by Wiley in Artificial Organs
- Vol. 50 (7) , 1052-1059
Initiation of Neurohormonal Blockade and Clinical Outcomes in HeartMate 3 LVAD Recipients During Index Implantation
Background: The use of neurohormonal blockade (NB), including beta‐blockers, mineralocorticoid receptor antagonists, and renin angiotensin system inhibitors, in patients after left ventricular assist device (LVAD) implantation is associated with improved clinical outcomes. However, its use during and soon after index LVAD implant discharge, a period of potential hemodynamic and laboratory vulnerability, and impact on outcomes in HeartMate 3 (HM3) recipients remain undefined and is the aim of the current study. Methods: A single‐center retrospective analysis was performed of patients undergoing HM3 LVAD implantation and discharged from index implant from January 2015 to December 2021. To align with contemporary management, we included sodium‐glucose cotransporter 2 inhibitors in the NB cohort. Patients on and not on any NB after index discharge were compared. Cox proportional hazards modeling was performed to investigate the association between the presence of NB with survival and heart failure (HF) readmission. Results: In total, 273 patients underwent HM3 LVAD implantation during the study period. The average implant age was 58 years, 75% were men, and 78% were Black patients. Of the 273 patients, 138 (50%) had a prescription of at least one NB agent after index discharge. Predictors of NB use included a history of stroke, perioperative renal replacement therapy, and index discharge creatinine level. An index discharge prescription for NB was associated with a lower risk of all‐cause mortality at a median follow‐up of 3.8 years (age‐sex‐race adjusted HR 0.63; 95% CI, 0.41–0.98; p = 0.042). The association was attenuated with additional adjustment for the predictors (HR 0.68; 95% CI, 0.43–1.08; p = 0.100). A discharge prescription for NB was not associated with HF readmission. Conclusion: While early initiation of NB therapy in HM3 LVAD recipients was associated with a lower risk of mortality, its clinical impact was attenuated after accounting for baseline and perioperative factors. These findings suggest that NB prescription may reflect underlying clinical stability and accordingly, results should be considered hypothesis‐generating and warrant prospective evaluation.
- 26 April 2026
- Published by Wiley in Artificial Organs
- Vol. 50 (7) , 1052-1059
Initiation of Neurohormonal Blockade and Clinical Outcomes in HeartMate 3 LVAD Recipients During Index Implantation
Background: The use of neurohormonal blockade (NB), including beta‐blockers, mineralocorticoid receptor antagonists, and renin angiotensin system inhibitors, in patients after left ventricular assist device (LVAD) implantation is associated with improved clinical outcomes. However, its use during and soon after index LVAD implant discharge, a period of potential hemodynamic and laboratory vulnerability, and impact on outcomes in HeartMate 3 (HM3) recipients remain undefined and is the aim of the current study. Methods: A single‐center retrospective analysis was performed of patients undergoing HM3 LVAD implantation and discharged from index implant from January 2015 to December 2021. To align with contemporary management, we included sodium‐glucose cotransporter 2 inhibitors in the NB cohort. Patients on and not on any NB after index discharge were compared. Cox proportional hazards modeling was performed to investigate the association between the presence of NB with survival and heart failure (HF) readmission. Results: In total, 273 patients underwent HM3 LVAD implantation during the study period. The average implant age was 58 years, 75% were men, and 78% were Black patients. Of the 273 patients, 138 (50%) had a prescription of at least one NB agent after index discharge. Predictors of NB use included a history of stroke, perioperative renal replacement therapy, and index discharge creatinine level. An index discharge prescription for NB was associated with a lower risk of all‐cause mortality at a median follow‐up of 3.8 years (age‐sex‐race adjusted HR 0.63; 95% CI, 0.41–0.98; p = 0.042). The association was attenuated with additional adjustment for the predictors (HR 0.68; 95% CI, 0.43–1.08; p = 0.100). A discharge prescription for NB was not associated with HF readmission. Conclusion: While early initiation of NB therapy in HM3 LVAD recipients was associated with a lower risk of mortality, its clinical impact was attenuated after accounting for baseline and perioperative factors. These findings suggest that NB prescription may reflect underlying clinical stability and accordingly, results should be considered hypothesis‐generating and warrant prospective evaluation.
- 18 March 2026
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 45 (7) , 1078-1080
Supporting the forgotten ventricle: Hybrid strategies for right heart failure in durable LVAD patients
- 18 March 2026
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 45 (7) , 1078-1080
Supporting the forgotten ventricle: Hybrid strategies for right heart failure in durable LVAD patients
- 20 February 2026
- Published by Elsevier in JACC: Heart Failure
- Vol. 14 (4) , 102995
Rethinking Lifelong Management of Heart Failure Care in Young Adults
- 20 February 2026
- Published by Elsevier in JACC: Heart Failure
- Vol. 14 (4) , 102995
Rethinking Lifelong Management of Heart Failure Care in Young Adults
- 22 January 2026
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 45 (8) , 1181-1192
The future of durable mechanical circulatory support devices: Emerging innovations
- 22 January 2026
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 45 (8) , 1181-1192
The future of durable mechanical circulatory support devices: Emerging innovations
- 16 January 2026
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 45 (5) , 825-826
Improving Intermacs profile assignments: Why reliability and reproducibility matter?
- 16 January 2026
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 45 (5) , 825-826
Improving Intermacs profile assignments: Why reliability and reproducibility matter?
- 5 January 2026
- Published by Elsevier in JACC: Heart Failure
- Vol. 14 (1) , 102757
Reply
- 11 December 2025
- Published by Elsevier in JACC: Heart Failure
- Vol. 14 (5) , 102833
When the Exception Becomes the Rule
- 11 December 2025
- Published by Elsevier in JACC: Heart Failure
- Vol. 14 (5) , 102833
When the Exception Becomes the Rule